Issue 46, 2021

ROS-responsive microcapsule assembly from Turkish galls for ulcerative colitis therapy

Abstract

Ulcerative colitis (UC) is a chronic, relapsing but nonspecific inflammatory bowel disease (IBD) that poses clinical challenges, as the fabrication of a safe, effective, and economical drug delivery system is still one of the biggest difficulties in drug therapy for UC. Herein, a galltannin-metal microcapsule (GTA–FeIII MCP) system coupled active constituents of Turkish gall and FeIII (Fe is one of the trace elements certified by the WHO) is reported for UC therapy. The hollow GTA–FeIII MCPs contain 4 categories of phenolic ligands, with an average particle size of 1.5 ± 0.5 μm and a double shell thickness of 38.1 ± 2.5 nm. When the concentration of the GTA–FeIII MCPs was greater than 250 μg mL−1, the H2O2 level decreased dramatically with the increase of incubation time and the GTA–FeIII MCPs gradually disassembled, demonstrating the anti-oxidant properties of GTA–FeIII MCPs, as well as their sensitivity and responsiveness to H2O2. Furthermore, the effects of anti-inflammatory and therapeutic efficacy against UC of GTA–FeIII MCPs had been confirmed. In vitro, IL-6, IL-1β, NO, TNF-α, and ROS levels were reduced by GTA–FeIII MCPs. In vivo, UC symptoms were ameliorated in mice given GTA–FeIII MCPs according to the disease activity index (DAI), colonic length shortening and pathological damage, myeloperoxidase (MPO) activity, and production of pro-inflammatory mediators. Consequently, this study provides a candidate drug carrier for anti-UC therapeutics, as well as new insights into the robustness of natural phenolic mixtures and solution-based metal sources.

Graphical abstract: ROS-responsive microcapsule assembly from Turkish galls for ulcerative colitis therapy

Supplementary files

Article information

Article type
Paper
Submitted
17 Mar 2021
Accepted
12 Oct 2021
First published
25 Oct 2021

New J. Chem., 2021,45, 21775-21787

ROS-responsive microcapsule assembly from Turkish galls for ulcerative colitis therapy

Y. Liu, J. Zang, M. Lv, R. Xue, X. Liu, Y. Hu, W. Yu, X. Wang and B. Han, New J. Chem., 2021, 45, 21775 DOI: 10.1039/D1NJ01303C

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements